This inventor holds 1 USPTO granted patent. Top assignees: Beth Israel Deaconess Medical Center, Inc., Dana-Farber-Cancer Institute Inc.. Active years: 2026.
Company Filing History:
1 out of 536 
1 out of 1,266 
Years Active: 2026
Title: Emily Erickson: Innovator in AKT Inhibition
Introduction
Emily Erickson is a prominent inventor based in Brookline, MA (US). She has made significant contributions to the field of cancer research through her innovative work on AKT inhibitors. Her research focuses on developing novel therapeutic strategies to combat diseases associated with dysfunctional AKT activity.
Latest Patents
Emily holds a patent for the "Degradation of AKT by conjugation of ATP-competitive AKT inhibitor GDC-0068 with E3 ligase ligands and methods of use." This patent describes bifunctional compounds that comprise a GDC-0068 analog, which binds to AKT isoforms AKT1, 2, and 3, along with a degron that binds an E3 ubiquitin ligase. These components are covalently attached by a linker, and the patent also covers pharmaceutical compositions and methods for treating diseases mediated by dysfunctional AKT activity. She has 1 patent to her name.
Career Highlights
Throughout her career, Emily has worked with esteemed institutions such as Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. Her work in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Emily has collaborated with notable colleagues, including Eric S. Fischer and Katherine Donovan. These partnerships have enhanced her research and expanded the impact of her innovations in cancer treatment.
Conclusion
Emily Erickson is a trailblazer in the field of AKT inhibition, with a focus on developing effective treatments for cancer. Her innovative patent and collaborations with leading institutions highlight her commitment to advancing medical science.